ASCELIA PHARMA AB
Research ASCELIA PHARMA AB (7ZA) on Bullrun: market cap EUR 6.45M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7ZA
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 6.45M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 16.38M
- Free cash flow-SEK 15.86M
Valuation Snapshot
latest market cap is EUR 6.45M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 76.25M | -SEK 72.31M | n/a | -0.69 | SEK 49.86M | SEK 970.00K | SEK 99.47M |
| FY2024 | SEK 0 | -SEK 80.03M | -SEK 62.84M | n/a | -1.48 | SEK 75.26M | SEK 25.23M | SEK 78.94M |
| FY2023 | SEK 0 | -SEK 109.29M | -SEK 126.79M | n/a | -3.24 | SEK 21.86M | SEK 0 | SEK 74.33M |
| FY2022 | SEK 0 | -SEK 131.22M | -SEK 125.26M | n/a | -3.77 | SEK 149.56M | n/a | SEK 180.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 6.45M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ASCELIA PHARMA AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ASCELIA PHARMA AB's market cap?
ASCELIA PHARMA AB's market capitalization is EUR 6.45M.
What does ASCELIA PHARMA AB do?
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.